Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada - Lung Cancer
Comparative effectiveness of pembrolizumab vs. nivolumab in patients with recurrent or advanced NSCLC | Scientific Reports
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) - Lung Cancer
BMS's Opdivo (nivolumab) Receives the US FDA's Approval as Neoadjuvant Treatment for Resectable Non-Small Cell
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer - Annals of Oncology
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases - Annals of Oncology
Immunotherapy in Advanced Lung Cancer
Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial - European
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | NEJM
Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer | NEJM
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis - The Lancet Oncology
CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non ...
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology
Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer | Journal of Clinical Oncology
Advanced Non-Small Cell Lung Cancer Clinical Trial Results | OPDIVO® ( nivolumab) + YERVOY® (ipilimumab)
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer☆ - ESMO Open
Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group - Journal of Geriatric Oncology
Major clinical trials of nivolumab in lung cancer. | Download Table
Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study - Lung Cancer
Nivolumab development, from preclinical experience to clinical... | Download Scientific Diagram
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer | NEJM
Efficacy and Safety of Nivolumab in Previously Treated Patients With Non–Small-cell Lung Cancer: Real World Experience in Argentina - Clinical Lung Cancer
Nivolumab: targeting PD-1 to bolster antitumor immunity | Future Oncology
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer | NEJM
Ongoing trials of nivolumab in advanced NSCLC. | Download Table
